8VU
(R)-4-((R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl)piperazine-2-one
Find entries where: 8VU
is present as a standalone ligand in 1 entries
Chemical Component Summary | |
---|---|
Name | (R)-4-((R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl)piperazine-2-one |
Identifiers | (3~{R})-4-[(3~{R})-3-azanyl-4-[2,4,5-tris(fluoranyl)phenyl]butanoyl]-3-[(2-methylpropan-2-yl)oxymethyl]piperazin-2-one |
Formula | C19 H26 F3 N3 O3 |
Molecular Weight | 401.423 |
Type | NON-POLYMER |
Isomeric SMILES | CC(C)(C)OC[C@@H]1C(=O)NCCN1C(=O)C[C@@H](Cc2cc(c(cc2F)F)F)N |
InChI | InChI=1S/C19H26F3N3O3/c1-19(2,3)28-10-16-18(27)24-4-5-25(16)17(26)8-12(23)6-11-7-14(21)15(22)9-13(11)20/h7,9,12,16H,4-6,8,10,23H2,1-3H3,(H,24,27)/t12-,16-/m1/s1 |
InChIKey | LCDDAGSJHKEABN-MLGOLLRUSA-N |
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 54 |
Chiral Atom Count | 2 |
Bond Count | 55 |
Aromatic Bond Count | 6 |
Drug Info: DrugBank
DrugBank ID | DB12625 |
---|---|
Name | Evogliptin |
Groups | investigational |
Description | Evogliptin has been used in trials studying the treatment and screening of Osteoporosis, Renal Impairment, Type 2 Diabetes Mellitus, Diabetes Mellitis Type 2, and Diabetes Mellitus, Type 2. |
Synonyms | Evogliptin |
Categories |
|
ATC-Code |
|
CAS number | 1222102-29-5 |
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL1779710 |
PubChem | 25022354 |
ChEMBL | CHEMBL1779710 |